Get the Stockscreener App
13.50
9.21%
-1.37
After Hours:
14.36
0.86
+6.37%
Ars Pharmaceuticals Inc stock is traded at $13.50, with a volume of 3.12M.
It is down -9.21% in the last 24 hours and down -23.25% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
See More
Previous Close:
$14.87
Open:
$14.9
24h Volume:
3.12M
Relative Volume:
2.11
Market Cap:
$1.33B
Revenue:
-
Net Income/Loss:
$-44.84M
P/E Ratio:
-28.72
EPS:
-0.47
Net Cash Flow:
$-44.23M
1W Performance:
-7.09%
1M Performance:
-23.25%
6M Performance:
+20.11%
1Y Performance:
+5.39%
1-Day Range:
$13.46
$14.97
1-Week Range:
$13.46
$15.09
52-Week Range:
$10.01
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Compare SPRY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
13.50 | 1.39B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
ARS Pharmaceuticals Inc. Breakout Confirmed by Volume Metrics2025 Price Momentum & Capital Efficient Trade Techniques - thegnnews.com
Moving Average Crossover Confirms Uptrend in ARS Pharmaceuticals Inc.Weekly Investment Summary & Verified Short-Term Plans - beatles.ru
Will ARS Pharmaceuticals Inc. Benefit From Sector TailwindsMarket Risk Analysis & Stepwise Trade Signal Implementation - newsyoung.net
ARS Pharmaceuticals (NASDAQ:SPRY) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway - simplywall.st
ARS Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
What institutions are buying ARS Pharmaceuticals Inc. stock nowLow Risk Trade Strategy Forecast - beatles.ru
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates - MSN
Is ARS Pharmaceuticals Inc. the Top Chart Pick This Week2025 Trading Recap & Safe Entry Momentum Stock Tips - sundaytimes.kr
ARS Pharmaceuticals Plunges 9.23%—What's Unraveling in the Lab? - AInvest
ARS Pharmaceuticals is Now Oversold (SPRY) - Nasdaq
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q2 2025 Earnings Call Transcript - Insider Monkey
ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James on strong neffy sales - Investing.com
ARS Pharmaceuticals signals continued neffy momentum with 180% prescription surge and global expansion targets - MSN
ARS Pharma Sales Jump 3,040% in Q2 - AOL.com
ARS Pharmaceuticals Reports Strong Growth for neffy - TipRanks
ARS Pharmaceuticals 2025 Q2 Earnings Sharp Revenue Surge Amid Widening Losses - AInvest
ARS Pharmaceuticals shares rise 1.07% after-hours after reporting Q2 revenue of $15.7 million and global expansion of neffy. - AInvest
ARS Pharma Sales Jump 3,040% in Q2 - The Motley Fool
ARS Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals' Q2 2025: Navigating Key Contradictions in DTC Impact, Inventory, and NUCLEUS Commercialization - AInvest
ARS Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
ARS Pharmaceuticals reports reports Q2 EPS (46c), consensus (51c) - TipRanks
SPRY Plummets 11.5%: What's Behind the Sharp Decline? - AInvest
Transcript : ARS Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
ARS Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: ARS Pharmaceuticals Q2 2025 revenue beats forecast - Investing.com
ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises - MarketScreener
ARS Pharmaceuticals earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
ARS Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Earnings Flash (SPRY) ARS Pharmaceuticals, Inc. Reports Q2 Revenue $15.7M, vs. FactSet Est of $13.8M - MarketScreener
ARS Pharmaceuticals Reports Second Quarter 2025 Financial - GlobeNewswire
ARS Pharmaceuticals Posts $15.7 Million Q2 Revenue, Neffy Sales Reach $12.8 Million in US. - AInvest
SPRY Furnishes Q2 Results and Posts Revised Investor Deck; Exhibits Included - Stock Titan
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray) - Yahoo Finance
TR | OpenAI4o Maintains ARS Pharmaceuticals(SPRY.US) With Hold Rating, Cuts Target Price to $16.5 - 富途牛牛
What drives ARS Pharmaceuticals Inc.’s stock priceShort-Term Explosive Growth - 선데이타임즈
What ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) 26% Share Price Gain Is Not Telling You - 富途牛牛
ARS Pharmaceuticals Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
ARS Pharmaceuticals SPRY 2025Q2 Earnings Preview Upside Potential Amid Strategic Developments - AInvest
What are the risks of holding ARS Pharmaceuticals Inc.Maximum Return Portfolio Ideas - thegnnews.com
ARS Pharmaceuticals: Pioneering a Needle-Free Revolution in Allergy Treatment - AInvest
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results - GlobeNewswire
ARS Pharmaceuticals to discuss Q2 2025 financial results Aug 13. - AInvest
ARS Pharmaceuticals Q2 Earnings Call: Anaphylaxis Treatment Leader Reports Latest Financial Results - Stock Titan
What drives ARS Pharmaceuticals Inc. stock priceCapitalize on emerging trends for profits - Jammu Links News
How volatile is ARS Pharmaceuticals Inc. stock compared to the marketBuild a portfolio that outperforms the market - Jammu Links News
How does ARS Pharmaceuticals Inc. compare to its industry peersAchieve breakthrough financial results today - Jammu Links News
What institutional investors are buying ARS Pharmaceuticals Inc. stockMarket-beating returns - Jammu Links News
Is ARS Pharmaceuticals Inc. a growth stock or a value stockMassive portfolio appreciation - Jammu Links News
What analysts say about ARS Pharmaceuticals Inc. stockIdentify undervalued stocks poised to rally - Jammu Links News
Is ARS Pharmaceuticals Inc. stock overvalued or undervaluedBuild a portfolio that grows with the market - Jammu Links News
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ars Pharmaceuticals Inc Stock (SPRY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Karas Eric | Chief Commercial Officer |
Jul 01 '25 |
Option Exercise |
1.50 |
15,000 |
22,500 |
25,315 |
| Karas Eric | Chief Commercial Officer |
Jul 01 '25 |
Sale |
16.99 |
15,000 |
254,860 |
10,315 |
| Flynn James E | 10% Owner |
Jun 27 '25 |
Sale |
18.46 |
740,149 |
13,663,151 |
4,887,254 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):